MDR1在卵巢癌患者不同部位表达的研究

The research of MDR1's expression in different parts of the ovarian cancer patients

目的检测多药耐药基因MDR1（Multidrug Resistance Gene 1）在卵巢癌患者卵巢癌组织、外周血白细胞和腹水癌细胞中的表达情况,探讨三者间的关系,更好的指导临床。方法标本取自2008年10月-2011年10月在河北联合大学附属医院就诊且手术的32例经临床及病理学证实为卵巢癌初治患者。年龄31~67岁之间,术中留取卵巢癌组织及其外周血各32例,腹水28例（4例患者无腹水）应用RT-PCR法检测卵巢癌组织及外周血和腹水中的MDR1的表达情况,并探讨其三者之间的相关性。结果 32例卵巢癌患者卵巢癌组织、外周血白细胞及腹水28例癌细胞中MDR1表达阳性率分别为（31.2%、21.9%、28.6%）,3种标本间差异无统计学意义（P〉0.05）。3种标本间2两检测,经统计学处理,差异无统计学意义（P〉0.05）,且两种标本间MDR1表达具有一致性。结论初治卵巢癌中卵巢癌组织与外周血白细胞及腹水癌细胞中的MDR1表达具有一致性。

Objective Objective Detection ovarian cancer patients ovarian cancer tissue and peripheral blood leukocyte and ascites in cancer drug Resistance Gene MDR1（ Multidrug Resistance Gene 1） expression,this paper discusses the relation among the three,better clinical guidance. Methods Specimens from October 2008 to October 2011 in hebei united university affiliated hospital and surgical patients,the clinical and pathology confirmed for ovarian cancer patients treated first 32 cases. In the age of 31 ~ 67 years old between,intraoperative return ovarian cancer organization and its peripheral blood all 32 cases,ascites and an example,（ 4 patients without ascites） application RT-PCR method to detect ovarian cancer tissue and peripheral blood and ascites MDR1 of expression,and discusses the relationship between the three. Results 32 cases of ovarian cancer patients ovarian cancer tissue and peripheral blood leukocyte and ascites and cases of cancer cells positive MDR1 express respectively（ 31. 2%,21. 9%,28. 6%）,three specimens difference was not statistically significant（ P〉0. 05）. Three kinds of specimen between two testing,after statistics processing,the difference was not statistically significant（ P〉0. 05）,and two kinds of specimen MDR1 between Express has consistency. Conclusion Beginning to ovarian cancer in ovarian cancer tissue and peripheral blood leukocyte and ascites cancer cells of MDR1 express has consistency.